Metabolic dysfunction–associated steatotic liver disease (MASLD) is a condition where fat accumulation and inflammation in the liver occurs. Our goal was to examine how different medication regimens used for type 2 diabetes, such as glucagon-like peptide 1 receptor analogs (GLP-1A) , sodium-glucose transport protein-2 inhibitors (SGLT2i ), Metformin and insulin(ins) alone are associated with different fibrosis scores (FIB-4) and lipid parameters and determine medication choices.
Dr. Sen is the Chief of Endocrinology at the Washington VA Medical Center, and Professor of Medicine and Biochemistry at GWU. His basic research interests involve behavior (survival and differentiation) of human adult stem cells in hyperglycemia. Dr. Sen’s current research projects include the effect of exercise, incretins & glucose transport inhibitors and artificial sweeteners on endothelial function and endothelial progenitor cells (EPCs) in patients with prediabetes and type 2 diabetes. Dr. Sen received a medical degree from Calcutta University and research training from the Royal College of Physicians in London and the University of Galway. He also completed a residency in internal medicine at Tufts University, and a fellowship in endocrinology at the National Institutes of Health.
